TriSCOPE combined cell-level predictive modeling, donor-aware differential expression and pseudotime analysis across six single-nucleus RNA-sequencing datasets (about 4.2 million nuclei from 627 donors). It identified cell-type-specific predictively expressed genes that were often missed by univariate differential-expression analysis; conditional GWAS–eQTL colocalization supported 27 gene–cell-type pairs at Alzheimer’s risk loci, including pairs without significant differential expression. Selected gene signals and analytical branches were compared across independent cohorts.
Technology: TriSCOPE, using LightGBM-based multivariate predictive modeling integrated with differential expression and pseudotime analysis
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Selected gene signals and analytical branches were compared across independent cohorts.
- Still unknown: This is a computational reanalysis of previously published, post-mortem cross-sectional datasets; it did not collect new tissue or perform perturbation experiments. The authors state the framework is for feature discovery rather than clinical prognosis, cannot establish temporal ordering, and requires functional perturbation studies to distinguish pathogenic drivers from protective or reactive signals. The reported cell-level AUCs are modest and should not be presented as patient-level diagnostic performance.
- AI role: The supervised machine-learning branch prioritized gene-expression features that predicted clinical Alzheimer’s diagnosis within cell types, conditional on demographics and APOE genotype. The study integrated those model-ranked features with donor-aware differential expression, pseudotime and GWAS–eQTL colocalization to nominate genetically supported cell-type programs.
Evidence sources: https://www.nature.com/articles/s41467-026-77651-5.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A closed-loop active-learning campaign for Borrelia burgdorferi whole-cell screening increased the experimental hit rate five-fold, from 0.2% in investigator-selected plates to 1.0% in the AL-guided campaign. The same study separately reports prospective in-silico selection of diverse compounds across bacterial species, with 11.0% experimental validation of predicted hits and 53-fold enrichment over investigator-directed screening; those validated compounds showed the intended narrow-spectrum B. burgdorferi activity. These are assay and screening results, not clinical efficacy.
Technology: Active learning using a directed message-passing neural network and evidential Dirichlet head
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: In a closed-loop Borrelia burgdorferi campaign, active-learning-guided selection produced a 1.0% experimental screening hit rate versus 0.2% in investigator-selected plates. A separate prospective in-silico selection across bacterial species achieved 11.0% experimental validation of predicted hits (53-fold enrichment over investigator-directed screening); the paper reports intended narrow-spectrum activity for B. burgdorferi.
- Still unknown: Preprint evidence is not independent replication or clinical testing. The cross-species hit-validation experiment is distinct from the closed-loop Borrelia hit-rate comparison. Direct full page retrieval was blocked; checked material was the primary indexed preprint and archived primary article text.
- AI role: A directed message-passing neural network with an evidential Dirichlet head supported active-learning compound selection for whole-cell inhibition testing; selected compounds were then experimentally screened.
Evidence sources: https://www.biorxiv.org/content/10.64898/2026.07.04.736489v1 · https://pmc.ncbi.nlm.nih.gov/articles/PMC13344992/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary bioRxiv indexed text, PubMed metadata/abstract and PMC indexed full-text excerpt; direct bioRxiv and PMC page loads were blocked..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Applied to about 30,000 patients with severe undiagnosed developmental disorders, it led to a diagnosis in about one-third of cases and identified variants in 123 previously unknown genes, 25 of which were independently confirmed by other labs. This is preliminary clinical use; further checks are needed before adoption, and the page gives no detailed metrics.
Technology: popEVE (variant-effect prediction model)
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: popEVE was tested on documented variants and case studies, and applied to about 30,000 undiagnosed patients, leading to a diagnosis in about one-third; 123 novel gene candidates were identified, and 25 were independently confirmed by other labs.
- Still unknown: The press article says popEVE will need further verification for safety and accuracy before wide clinical adoption, and gives no accuracy metrics; it is not yet in routine clinical use.
- AI role: A deep generative model extending EVE with a protein language model, producing a calibrated disease-likelihood score for each variant.
Evidence sources: https://hms.harvard.edu/news/new-artificial-intelligence-model-could-speed-rare-disease-diagnosis · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41588-025-02400-1&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The model covers about 8,000 drugs across 17,080 diseases and is nearly 50% better than competitors at identifying candidates and 35% more accurate on contraindications. It was tested on 1.2 million medical records and on three rare diseases excluded from training. Computational predictions only, with no laboratory or clinical confirmation.
Technology: TxGNN (graph neural network)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The model was checked against about 8,000 drugs and 17,080 diseases, validated on 1.2 million medical records, and asked to find drugs for three rare diseases excluded from training; it was compared with leading drug-repurposing models.
- Still unknown: Identified therapies would require further evaluation for dosing and delivery, and there is no laboratory or clinical confirmation.
- AI role: Proposed existing drugs for thousands of diseases, predicted contraindications and side effects, and gave a rationale for each prediction.
Evidence sources: https://hms.harvard.edu/news/researchers-harness-ai-repurpose-existing-drugs-treatment-rare-diseases
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 303 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Trained on 15 million patches and 60,000 slides and tested on more than 19,400 slides from 32 datasets and 24 hospitals: it detects cancer with about 94% accuracy across 15 datasets, predicts mutations in 54 genes with over 70% accuracy, and improves survival prediction by 8% across 17 institutions. Retrospective validation; not trained on rare diseases or premalignant tissue.
Technology: CHIEF (pathology foundation model)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Retrospective validation on more than 19,400 slides from 32 datasets at 24 hospitals; cancer detection was about 94% accurate across datasets.
- Still unknown: Validation beyond these datasets is still needed, rare and non-cancerous conditions and pre-malignant tissue were not tested, and gene prediction accuracy varies by gene and cancer type.
- AI role: Read digital tumor slides to detect cancer, predict gene mutations and survival, and generate heat maps of tissue features for pathologists.
Evidence sources: https://hms.harvard.edu/news/new-artificial-intelligence-tool-cancer
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 685 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A framework combining single-cell ATAC-seq, motif analysis, topic modeling, machine learning and genetic variation identified SMARCC1 as a previously unrecognized controller of regulatory T-cell chromatin programs. CRISPR-Cas9 deletion of Smarcc1 in Tregs produced the predicted loss of accessibility in topic-3 regulatory regions, supporting the computationally inferred connection.
Technology: Integrated machine-learning framework using topic modeling and high-density genetic variation over single-cell ATAC-seq profiles
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A framework combining single-cell ATAC-seq, motif analysis, topic modeling, machine learning and genetic variation identified SMARCC1 as a previously unrecognized controller of regulatory T-cell chromatin programs.
- Still unknown: CRISPR validation supported the predicted SMARCC1 effect for topic 3; topic 10 was not represented and the authors note possible redundancy with SMARCC2. The result concerns regulatory chromatin programs in Tregs, not clinical or therapeutic outcomes.
- AI role: The framework organized co-varying open chromatin regions into Treg regulatory modules, inferred transcription-factor effects on those programs, and nominated SMARCC1 as a regulator of topic-3/10 accessibility. The team tested the prediction by CRISPR-Cas9 editing Tregs and profiling chromatin accessibility.
Evidence sources: https://cbdm.hms.harvard.edu/assets/Publications/2024pub/chowdharyPNAS.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 32 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers combined a genetic chemical-proximity platform and experimental screening of 72 Mycobacterium smegmatis protein candidates with machine learning. A Lasso model trained on measured degradation data identified N-terminal disorder propensity as associated with degradation potential and predicted candidate targets among 348 essential proteins conserved between M. smegmatis and M. tuberculosis. Experimentally induced degradation of selected essential M. smegmatis proteins inhibited bacterial growth and, for some targets, potentiated antimicrobial compounds.
Technology: Lasso regression model trained on sequence and structural protein descriptors, including AlphaFold2 confidence and predicted disorder propensity
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Researchers combined a genetic chemical-proximity platform and experimental screening of 72 Mycobacterium smegmatis protein candidates with machine learning.
- Still unknown: Most mechanistic and growth evidence was generated in M. smegmatis, a non-pathogenic model, not in clinical treatment or an animal efficacy study. The machine-learning target predictions for the larger set of 348 essential proteins require orthogonal experimental validation. The study reports that targeted degradation of some proteins inhibits growth and potentiates antimicrobials; this does not establish a deployable drug or clinical benefit. Primary paper source checked; no independent replication assessed.
- AI role: Machine learning connected measured degradation constants from experimentally screened protein substrates to protein sequence/structure features, identifying N-terminal disorder propensity as a predictor of degradation potential; the trained model then ranked candidate targets among essential proteins conserved between M. smegmatis and M. tuberculosis. Experiments—not the model alone—showed degradation and antibacterial phenotypes for selected targets.
Evidence sources: https://www.nature.com/articles/s41467-024-48506-8
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 28 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Starting from January 2020, the tool predicted SARS-CoV-2 mutations with accuracy similar to experimental antibody-binding assays and ranked their prevalence better; it generalizes to HIV and influenza. Retrospective validation; prospective performance is not reported.
Technology: EVEscape
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: EVEscape was trained only on pre-2020 sequences and compared against high-throughput experimental scans of SARS-CoV-2 variation that later emerged, a retrospective validation; prospective performance is not reported.
- Still unknown: The abstract states no limitations; the page says testing on Lassa and Nipah is ongoing and vaccine or therapy use against future variants is a future application.
- AI role: A deep learning model of historical viral sequences, combined with biophysical and structural information, scored the escape potential of mutations.
Evidence sources: https://hms.harvard.edu/news/ai-tool-can-help-forecast-viral-outbreaks · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06617-0&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 245 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep learning system analysing gigapixel endomyocardial biopsy slides detected allograft rejection with an AUC of 0.962, distinguished cellular and antibody-mediated rejection (AUCs 0.958 and 0.874) and graded rejection with an AUC of 0.833. In a human reader study it was non-inferior to conventional assessment and reduced interobserver variability and assessment time. Caveat: test cohorts from the US, Turkey and Switzerland are retrospective and the authors call for clinical trials.
Technology: Deep learning on whole-slide images for endomyocardial biopsies
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Rejection detection (AUC 0.962) was measured on a curated US dataset and independent test cohorts from Turkey and Switzerland, and a human reader study found the system non-inferior to conventional assessment.
- Still unknown: The authors state that clinical trials are needed to establish the efficacy of AI-assisted biopsy assessment.
- AI role: Deep learning system analysed gigapixel endomyocardial biopsy whole-slide images to detect, subtype and grade rejection.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-022-01709-2&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 105 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.